GlassScriptPhysician profile
John M Yalam
NPI 1568434819
$9,000.95
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,565 · 2020: $101 · 2021: $65.47 · 2022: $95.13 · 2023: $150 · 2024: $25.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $127 · Food and Beverage: $47.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $127.22 |
| Food and Beverage | $47.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $8,494.89 | 2019 | |
| Gilead Sciences, INC. | $137.05 | 2019-2021 | |
| Braintree Laboratories, INC. | $133.01 | 2020-2022 | |
| Pentax of America, INC. | $127.22 | 2023 | Plasmatyphoon |
| Ironwood Pharmaceuticals, INC | $33.88 | 2019 | |
| Abbvie INC. | $25.07 | 2024 | |
| Nestle Healthcare Nutrition INC. | $22.54 | 2023 | |
| Oxford Immunotec USA INC | $15.44 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.85 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$44,503.96 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Yalam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.